Exact Sciences Key Executives
This section highlights Exact Sciences's key executives, including their titles and compensation details.
Find Contacts at Exact Sciences
(Showing 0 of )
Exact Sciences Earnings
This section highlights Exact Sciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-19 | $-0.29 | $-0.06 |
| Read Transcript | Q3 | 2024 | 2024-11-05 | $-0.20 | $-0.21 |
| Read Transcript | Q2 | 2024 | 2024-07-31 | $-0.37 | $-0.09 |
| Read Transcript | Q1 | 2024 | 2024-05-08 | $-0.47 | $-0.50 |
| Read Transcript | Q4 | 2023 | 2024-02-21 | $-0.53 | $-0.27 |
| Read Transcript | Q3 | 2023 | 2023-11-01 | $-0.48 | $0.00 |
| Read Transcript | Q2 | 2023 | 2023-08-01 | $-0.50 | $-0.45 |
| Read Transcript | Q1 | 2023 | 2023-05-09 | $-0.79 | $-0.42 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
$43.45
Stock Price
$8.07B
Market Cap
25.00K
Employees
Madison, WI
Location
Financial Statements
Access annual & quarterly financial statements for Exact Sciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.76B | $2.50B | $2.08B | $1.77B | $1.49B |
| Cost of Revenue | $840.15M | $654.25M | $574.39M | $458.76M | $354.32M |
| Gross Profit | $1.92B | $1.85B | $1.51B | $1.31B | $1.14B |
| Gross Profit Ratio | 69.55% | 73.80% | 72.44% | 74.00% | 76.24% |
| Research and Development Expenses | $431.21M | $425.88M | $393.42M | $385.65M | $554.05M |
| General and Administrative Expenses | $781.83M | $1.42B | $737.30M | $801.26M | $481.72M |
| Selling and Marketing Expenses | $894.12M | $203.90M | $846.01M | $861.89M | $589.92M |
| Selling General and Administrative Expenses | $1.68B | $1.62B | $1.58B | $1.66B | $1.07B |
| Other Expenses | $868.06M | $-3.69M | $110.69M | $95.00M | $69.73M |
| Operating Expenses | $2.97B | $2.06B | $2.09B | $2.14B | $1.70B |
| Cost and Expenses | $3.81B | $2.71B | $2.66B | $2.60B | $2.05B |
| Interest Income | $-5.30M | $-5.35M | $19.63M | $1.79M | $6.57M |
| Interest Expense | $31.97M | $24.42M | $19.63M | $18.61M | $95.98M |
| Depreciation and Amortization | $214.86M | $206.61M | $226.20M | $206.17M | $179.08M |
| EBITDA | $-789.33M | $41.88M | $-386.74M | $-617.73M | $-632.86M |
| EBITDA Ratio | -28.61% | 1.68% | -23.03% | -41.90% | -31.18% |
| Operating Income | $-1.05B | $-215.01M | $-577.54M | $-835.47M | $-558.35M |
| Operating Income Ratio | -38.01% | -8.60% | -27.71% | -47.28% | -37.44% |
| Total Other Income Expenses Net | $27.15M | $13.27M | $-39.06M | $13.17M | $-61.37M |
| Income Before Tax | $-1.02B | $-201.75M | $-632.57M | $-842.51M | $-857.11M |
| Income Before Tax Ratio | -37.03% | -8.07% | -30.35% | -47.68% | -57.47% |
| Income Tax Expense | $7.30M | $2.40M | $-9.06M | $-246.88M | $-8.57M |
| Net Income | $-1.03B | $-204.15M | $-623.51M | $-595.62M | $-848.53M |
| Net Income Ratio | -37.29% | -8.17% | -29.91% | -33.71% | -56.90% |
| EPS | $-5.59 | $-1.13 | $-3.54 | $-3.48 | $-5.61 |
| EPS Diluted | $-5.59 | $-1.13 | $-3.54 | $-3.48 | $-5.61 |
| Weighted Average Shares Outstanding | 184.20M | 180.14M | 176.35M | 171.35M | 151.14M |
| Weighted Average Shares Outstanding Diluted | 184.20M | 180.14M | 176.35M | 171.35M | 151.14M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $713.42M | $708.65M | $699.26M | $637.52M | $646.88M | $628.34M | $622.09M | $602.45M | $553.00M | $523.07M | $521.64M | $486.57M | $473.81M | $456.38M | $434.82M | $402.08M | $466.34M | $408.36M | $268.87M | $347.82M |
| Cost of Revenue | $284.20M | $196.10M | $213.16M | $170.10M | $171.82M | $168.53M | $156.99M | $156.87M | $147.15M | $147.90M | $144.60M | $134.70M | $119.06M | $115.70M | $114.00M | $110.00M | $99.77M | $95.10M | $77.89M | $81.60M |
| Gross Profit | $429.22M | $512.55M | $486.11M | $467.42M | $475.07M | $459.81M | $465.10M | $445.58M | $405.84M | $375.17M | $377.04M | $351.87M | $354.75M | $340.68M | $320.82M | $292.08M | $366.57M | $313.26M | $190.98M | $266.22M |
| Gross Profit Ratio | 60.16% | 72.30% | 69.50% | 73.30% | 73.40% | 73.20% | 74.80% | 74.00% | 73.40% | 71.70% | 72.30% | 72.30% | 74.90% | 74.60% | 73.80% | 72.60% | 78.61% | 76.71% | 71.03% | 76.54% |
| Research and Development Expenses | $99.62M | $100.10M | $120.88M | $110.61M | $114.92M | $111.45M | $104.09M | $95.42M | $94.27M | $90.81M | $106.08M | $102.25M | $88.49M | $75.36M | $106.23M | $115.57M | $446.40M | $31.47M | $32.67M | $43.51M |
| General and Administrative Expenses | $191.11M | $217.20M | $335.40M | $385.10M | $353.45M | $217.39M | $237.97M | $217.29M | $193.89M | $313.70M | $324.80M | $169.80M | $179.37M | $186.50M | $167.60M | $267.70M | $145.45M | $115.60M | $106.69M | $114.00M |
| Selling and Marketing Expenses | $244.53M | $194.65M | $51.80M | $50.40M | $57.59M | $173.16M | $176.49M | $186.96M | $210.21M | $66.00M | $72.80M | $232.18M | $284.30M | $196.62M | $194.83M | $186.14M | $166.83M | $136.48M | $118.86M | $167.75M |
| Selling General and Administrative Expenses | $435.64M | $411.90M | $387.13M | $435.50M | $411.03M | $390.55M | $414.45M | $404.26M | $404.11M | $379.70M | $397.60M | $401.98M | $463.67M | $383.12M | $362.43M | $453.84M | $312.28M | $252.08M | $225.55M | $281.75M |
| Other Expenses | $770.32M | $39.96M | $31.46M | $27.76M | $23.31M | $22.99M | $23.48M | $22.93M | $22.91M | $36.77M | $26.36M | $24.65M | $24.05M | $23.94M | $23.82M | $23.19M | $23.20M | $23.43M | $-235.00K | $23.34M |
| Operating Expenses | $1.31B | $551.96M | $508.01M | $569.69M | $542.87M | $452.96M | $541.48M | $522.61M | $521.29M | $507.28M | $530.04M | $528.88M | $576.20M | $482.41M | $492.49M | $592.60M | $781.88M | $306.98M | $257.99M | $348.60M |
| Cost and Expenses | $1.59B | $748.06M | $721.17M | $739.79M | $714.68M | $621.49M | $698.47M | $679.47M | $668.45M | $655.18M | $674.64M | $663.58M | $695.26M | $598.11M | $606.49M | $702.60M | $881.64M | $402.08M | $335.88M | $430.20M |
| Interest Income | $-1.33M | $11.58M | $- | $- | $- | $6.25B | $2.99M | $14.43M | $5.41M | $5.24M | $- | $463.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $8.25M | $8.94M | $111.00K | $7.94M | $6.54M | $7.87M | $7.82M | $3.38M | $5.41M | $3.79M | $3.08M | $3.07M | $4.66M | $3.24M | $3.22M | $4.62M | $24.34M | $1.96M | $1.39M | $16.38M |
| Depreciation and Amortization | $53.15M | $54.77M | $53.00M | $53.94M | $54.17M | $59.40M | $57.41M | $56.55M | $53.67M | $55.74M | $61.77M | $55.01M | $52.60M | $52.75M | $51.42M | $49.44M | $23.20M | $43.14M | $23.43M | $39.34M |
| EBITDA | $-814.57M | $26.28M | $34.87M | $-46.54M | $11.66M | $68.31M | $-25.99M | $-27.35M | $-70.85M | $-90.90M | $-101.53M | $-132.70M | $-167.59M | $-113.37M | $-116.81M | $-219.91M | $-369.44M | $-153.49M | $-26.37M | $-82.37M |
| EBITDA Ratio | -114.18% | 3.71% | 4.45% | -7.58% | -2.32% | 4.75% | -8.59% | -9.05% | -16.73% | -16.25% | -19.66% | -26.87% | -41.66% | -21.27% | -29.38% | -63.88% | -84.08% | 11.84% | -16.21% | -12.61% |
| Operating Income | $-876.35M | $-39.40M | $-21.91M | $-106.69M | $-67.84M | $6.85M | $-76.93M | $-77.02M | $-115.45M | $-132.11M | $-153.00M | $-177.01M | $-221.45M | $-162.02M | $-171.66M | $-300.54M | $-415.30M | $-203.34M | $-67.01M | $-82.37M |
| Operating Income Ratio | -122.84% | -5.56% | -3.13% | -16.74% | -10.49% | 1.09% | -12.37% | -12.78% | -20.88% | -25.26% | -29.33% | -36.38% | -46.74% | -35.50% | -39.48% | -74.75% | -89.06% | -49.79% | -24.92% | -23.68% |
| Total Other Income Expenses Net | $23.15M | $1.98M | $11.91M | $-1.73M | $17.46M | $-5.81M | $-2.99M | $4.60M | $-11.04M | $-13.82M | $-8.23M | $-5.96M | $-3.40M | $-8.77M | $-1.22M | $26.57M | $-23.29M | $-1.96M | $-1.39M | $-54.51M |
| Income Before Tax | $-853.20M | $-37.43M | $-14.35M | $-108.42M | $-50.38M | $1.04M | $-79.92M | $-72.49M | $-129.93M | $-151.88M | $-167.81M | $-182.95M | $-224.85M | $-170.80M | $-172.89M | $-273.97M | $-438.27M | $-224.39M | $-87.01M | $-107.43M |
| Income Before Tax Ratio | -119.59% | -5.28% | -2.05% | -17.01% | -7.79% | 0.17% | -12.85% | -12.03% | -23.50% | -29.04% | -32.17% | -37.60% | -47.46% | -37.42% | -39.76% | -68.14% | -93.98% | -54.95% | -32.36% | -30.89% |
| Income Tax Expense | $11.38M | $808.00K | $1.46M | $1.81M | $-610.00K | $249.00K | $1.11M | $1.66M | $-2.18M | $-3.12M | $-1.75M | $-2.02M | $-4.24M | $-3.86M | $4.03M | $-242.81M | $-1.46M | $-4.51M | $-867.00K | $-1.73M |
| Net Income | $-864.59M | $-38.24M | $-15.81M | $-110.23M | $-49.77M | $794.00K | $-81.03M | $-74.15M | $-127.75M | $-148.76M | $-166.06M | $-180.94M | $-220.61M | $-166.94M | $-176.91M | $-31.16M | $-436.81M | $-219.88M | $-86.14M | $-105.70M |
| Net Income Ratio | -121.19% | -5.40% | -2.26% | -17.29% | -7.69% | 0.13% | -13.02% | -12.31% | -23.10% | -28.44% | -31.83% | -37.19% | -46.56% | -36.58% | -40.69% | -7.75% | -93.67% | -53.85% | -32.04% | -30.39% |
| EPS | $-4.67 | $-0.21 | $-0.09 | $-0.60 | $-0.27 | $0.00 | $-0.45 | $-0.42 | $-0.72 | $-0.84 | $-0.94 | $-1.04 | $-1.28 | $-0.97 | $-1.03 | $-0.18 | $-2.79 | $-1.46 | $-0.58 | $-0.71 |
| EPS Diluted | $-4.67 | $-0.21 | $-0.09 | $-0.60 | $-0.27 | $0.00 | $-0.45 | $-0.42 | $-0.72 | $-0.84 | $-0.94 | $-1.04 | $-1.28 | $-0.97 | $-1.03 | $-0.18 | $-2.79 | $-1.46 | $-0.58 | $-0.71 |
| Weighted Average Shares Outstanding | 185.31M | 184.79M | 184.31M | 182.35M | 181.11M | 180.65M | 180.20M | 178.57M | 177.58M | 177.00M | 176.36M | 173.98M | 172.45M | 171.98M | 171.49M | 169.43M | 156.47M | 150.16M | 149.73M | 148.15M |
| Weighted Average Shares Outstanding Diluted | 185.31M | 184.79M | 184.31M | 182.35M | 181.11M | 184.07M | 180.20M | 178.57M | 177.58M | 177.00M | 176.36M | 174.42M | 172.45M | 171.98M | 171.49M | 169.43M | 156.47M | 150.16M | 149.73M | 148.15M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $600.89M | $605.38M | $242.49M | $315.47M | $1.49B |
| Short Term Investments | $437.14M | $172.27M | $389.56M | $715.00M | $348.70M |
| Cash and Short Term Investments | $1.04B | $777.64M | $632.06M | $1.03B | $1.84B |
| Net Receivables | $248.97M | $203.62M | $158.04M | $216.65M | $233.19M |
| Inventory | $162.38M | $127.47M | $118.26M | $104.99M | $92.27M |
| Other Current Assets | $122.05M | $85.63M | $73.90M | $74.12M | $66.31M |
| Total Current Assets | $1.57B | $1.19B | $982.26M | $1.43B | $2.20B |
| Property Plant Equipment Net | $810.62M | $842.06M | $851.76M | $754.47M | $576.63M |
| Goodwill | $2.37B | $2.37B | $2.35B | $2.34B | $1.24B |
| Intangible Assets | $1.01B | $1.89B | $1.96B | $2.09B | $848.43M |
| Goodwill and Intangible Assets | $3.38B | $4.26B | $4.30B | $4.43B | $2.09B |
| Long Term Investments | $- | $- | $47.50M | $33.40M | $29.41M |
| Tax Assets | $- | $- | $468.55M | $492.51M | $227.43M |
| Other Non-Current Assets | $169.72M | $177.39M | $-425.47M | $-451.32M | $-193.06M |
| Total Non-Current Assets | $4.36B | $5.28B | $5.24B | $5.26B | $2.73B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $5.93B | $6.47B | $6.23B | $6.68B | $4.93B |
| Account Payables | $89.57M | $78.82M | $74.92M | $67.83M | $35.71M |
| Short Term Debt | $276.56M | $79.38M | $31.57M | $25.91M | $330.22M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $3.10M | $398.56M | $233.60M |
| Other Current Liabilities | $366.06M | $356.51M | $306.26M | $423.33M | $267.17M |
| Total Current Liabilities | $732.19M | $514.70M | $412.75M | $517.07M | $575.84M |
| Long Term Debt | $2.48B | $2.48B | $2.42B | $2.36B | $2.02B |
| Deferred Revenue Non-Current | $- | $- | $-488.26M | $-521.30M | $-236.73M |
| Deferred Tax Liabilities Non-Current | $- | $- | $488.26M | $521.30M | $236.73M |
| Other Non-Current Liabilities | $315.50M | $335.98M | $352.46M | $417.78M | $37.34M |
| Total Non-Current Liabilities | $2.79B | $2.81B | $2.77B | $2.78B | $1.53B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $3.53B | $3.33B | $3.18B | $3.30B | $2.10B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.86M | $1.81M | $1.78M | $1.74M | $1.59M |
| Retained Earnings | $-4.50B | $-3.47B | $-3.27B | $-2.64B | $-1.97B |
| Accumulated Other Comprehensive Income Loss | $-944.00K | $1.43M | $-5.24M | $-1.44M | $526.00K |
| Other Total Stockholders Equity | $6.90B | $6.61B | $6.31B | $6.03B | $4.28B |
| Total Stockholders Equity | $2.40B | $3.15B | $3.04B | $3.39B | $2.82B |
| Total Equity | $2.40B | $3.15B | $3.04B | $3.39B | $2.82B |
| Total Liabilities and Stockholders Equity | $5.93B | $6.47B | $6.23B | $6.68B | $4.93B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.93B | $6.47B | $6.23B | $6.68B | $4.93B |
| Total Investments | $437.14M | $172.27M | $389.56M | $715.00M | $348.70M |
| Total Debt | $2.75B | $2.55B | $2.45B | $2.36B | $1.46B |
| Net Debt | $2.15B | $1.95B | $2.20B | $2.05B | $-27.11M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $600.89M | $588.83M | $530.18M | $347.49M | $605.38M | $594.61M | $604.36M | $421.37M | $242.49M | $235.31M | $213.42M | $189.78M | $315.47M | $273.78M | $363.71M | $1.10B | $1.49B | $806.68M | $703.93M | $701.05M |
| Short Term Investments | $437.14M | $432.30M | $416.60M | $304.61M | $172.27M | $139.79M | $171.35M | $277.28M | $389.56M | $433.81M | $514.62M | $627.20M | $715.00M | $944.69M | $943.86M | $274.15M | $348.70M | $476.32M | $518.73M | $530.06M |
| Cash and Short Term Investments | $1.04B | $1.02B | $946.78M | $652.09M | $777.64M | $734.41M | $775.71M | $698.65M | $632.06M | $669.11M | $728.04M | $816.98M | $1.03B | $1.22B | $1.31B | $1.38B | $1.84B | $1.28B | $1.22B | $1.23B |
| Net Receivables | $248.97M | $264.82M | $287.96M | $240.58M | $203.62M | $199.40M | $178.32M | $183.37M | $158.04M | $189.21M | $186.54M | $205.62M | $216.65M | $249.57M | $226.54M | $256.13M | $233.19M | $206.61M | $163.61M | $140.05M |
| Inventory | $162.38M | $136.99M | $127.37M | $128.53M | $127.47M | $132.84M | $130.77M | $124.09M | $118.26M | $114.70M | $115.17M | $112.96M | $104.99M | $95.17M | $89.81M | $89.03M | $92.27M | $80.43M | $82.22M | $69.42M |
| Other Current Assets | $122.05M | $110.18M | $200.63M | $99.06M | $85.63M | $81.54M | $89.13M | $85.27M | $73.90M | $75.49M | $71.88M | $79.58M | $74.12M | $52.38M | $45.28M | $52.17M | $33.16M | $36.59M | $36.38M | $43.73M |
| Total Current Assets | $1.57B | $1.53B | $1.45B | $1.12B | $1.19B | $1.15B | $1.17B | $1.09B | $982.26M | $1.05B | $1.10B | $1.22B | $1.43B | $1.62B | $1.67B | $1.78B | $2.20B | $1.61B | $1.50B | $1.48B |
| Property Plant Equipment Net | $810.62M | $812.78M | $864.29M | $844.06M | $842.06M | $842.08M | $835.29M | $841.36M | $851.76M | $846.45M | $846.15M | $792.99M | $754.47M | $692.11M | $668.82M | $644.42M | $576.63M | $586.29M | $596.19M | $589.85M |
| Goodwill | $2.37B | $2.37B | $2.37B | $2.37B | $2.37B | $2.37B | $2.35B | $2.35B | $2.35B | $2.35B | $2.35B | $2.34B | $2.34B | $2.24B | $2.24B | $2.18B | $1.24B | $1.24B | $1.24B | $1.24B |
| Intangible Assets | $1.01B | $1.86B | $1.84B | $1.87B | $1.89B | $1.91B | $1.91B | $1.93B | $1.96B | $1.98B | $2.05B | $2.07B | $2.09B | $2.04B | $2.09B | $2.07B | $848.43M | $871.66M | $1.11B | $1.13B |
| Goodwill and Intangible Assets | $3.38B | $4.23B | $4.21B | $4.23B | $4.26B | $4.28B | $4.26B | $4.28B | $4.30B | $4.32B | $4.39B | $4.40B | $4.43B | $4.29B | $4.33B | $4.26B | $2.09B | $2.11B | $2.34B | $2.37B |
| Long Term Investments | $- | $- | $17.24M | $11.00M | $14.90M | $40.60M | $45.10M | $48.60M | $47.50M | $16.10M | $59.40M | $36.20M | $33.40M | $23.00M | $27.00M | $26.98M | $29.10M | $23.90M | $11.80M | $11.80M |
| Tax Assets | $- | $- | $1 | $-11.00M | $450.04M | $-40.60M | $-45.10M | $-48.60M | $468.55M | $-16.10M | $-59.40M | $-36.20M | $492.51M | $-23.00M | $-27.00M | $-26.98M | $-29.10M | $-23.90M | $-11.80M | $-11.80M |
| Other Non-Current Assets | $- | $170.82M | $128.83M | $178.09M | $-287.55M | $150.75M | $89.54M | $91.87M | $-425.47M | $88.74M | $96.68M | $77.48M | $-451.32M | $59.24M | $54.66M | $56.95M | $63.77M | $52.12M | $23.90M | $21.54M |
| Total Non-Current Assets | $4.19B | $5.22B | $5.22B | $5.26B | $5.28B | $5.27B | $5.18B | $5.21B | $5.24B | $5.26B | $5.34B | $5.28B | $5.26B | $5.04B | $5.06B | $4.96B | $2.73B | $2.75B | $2.96B | $2.98B |
| Other Assets | $169.72M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $5.93B | $6.75B | $6.67B | $6.38B | $6.47B | $6.42B | $6.36B | $6.30B | $6.23B | $6.31B | $6.44B | $6.49B | $6.68B | $6.65B | $6.72B | $6.73B | $4.93B | $4.35B | $4.47B | $4.46B |
| Account Payables | $89.57M | $97.65M | $52.98M | $60.50M | $78.82M | $73.56M | $75.08M | $86.71M | $74.92M | $63.58M | $84.17M | $66.47M | $67.83M | $41.72M | $36.59M | $34.70M | $35.71M | $26.06M | $31.00M | $38.05M |
| Short Term Debt | $249.15M | $276.21M | $283.32M | $332.44M | $83.78M | $84.69M | $83.67M | $33.21M | $31.57M | $30.15M | $28.41M | $26.11M | $25.91M | $339.54M | $336.28M | $334.34M | $330.22M | $16.07M | $21.06M | $41.89M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $265.12M | $341.68M | $-73.56M | $- | $- | $3.10M | $2.30M | $1.20M | $1.30M | $398.56M | $304.71M | $266.00M | $214.14M | $233.60M | $182.94M | $139.50M | $166.60M |
| Other Current Liabilities | $144.31M | $349.80M | $332.34M | $292.18M | $352.11M | $318.27M | $329.31M | $247.43M | $306.26M | $329.94M | $330.75M | $388.37M | $423.33M | $328.97M | $302.83M | $259.87M | $209.92M | $210.71M | $170.22M | $163.64M |
| Total Current Liabilities | $483.03M | $723.66M | $668.64M | $685.11M | $514.70M | $476.51M | $488.06M | $367.35M | $412.75M | $423.68M | $443.33M | $480.95M | $517.07M | $710.23M | $675.70M | $628.91M | $575.84M | $252.83M | $222.27M | $243.58M |
| Long Term Debt | $2.48B | $2.48B | $2.50B | $2.24B | $2.48B | $2.48B | $2.48B | $2.53B | $2.43B | $2.42B | $2.42B | $2.36B | $2.37B | $2.05B | $2.05B | $2.04B | $1.48B | $1.70B | $1.68B | $1.63B |
| Deferred Revenue Non-Current | $- | $- | $182.66M | $-18.20M | $-467.32M | $-18.70M | $-19.80M | $-20.10M | $-488.26M | $-22.90M | $-27.40M | $-26.40M | $-521.30M | $-32.70M | $-37.50M | $-38.90M | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $19.10M | $18.20M | $467.32M | $18.70M | $19.80M | $20.10M | $488.26M | $22.90M | $27.40M | $26.40M | $521.30M | $32.70M | $37.50M | $38.90M | $- | $- | $- | $- |
| Other Non-Current Liabilities | $315.50M | $332.21M | $311.68M | $298.08M | $335.98M | $341.77M | $330.82M | $344.38M | $345.06M | $355.00M | $364.11M | $389.06M | $405.28M | $436.58M | $439.18M | $414.19M | $47.58M | $62.82M | $50.31M | $47.25M |
| Total Non-Current Liabilities | $2.79B | $2.81B | $2.81B | $2.56B | $2.81B | $2.82B | $2.81B | $2.88B | $2.77B | $2.77B | $2.78B | $2.75B | $2.78B | $2.49B | $2.49B | $2.46B | $1.53B | $1.76B | $1.73B | $1.68B |
| Other Liabilities | $249.15M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $3.53B | $3.54B | $3.48B | $3.24B | $3.33B | $3.30B | $3.30B | $3.25B | $3.18B | $3.20B | $3.23B | $3.23B | $3.30B | $3.20B | $3.17B | $3.09B | $2.10B | $2.02B | $1.96B | $1.92B |
| Preferred Stock | $- | $- | $- | $- | $3.47B | $3.42B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $1.85M | $1.85M | $1.84M | $1.81M | $1.81M | $1.81M | $1.80M | $1.78M | $1.77M | $1.77M | $1.76M | $1.74M | $1.72M | $1.72M | $1.71M | $1.59M | $1.50M | $1.50M | $1.50M |
| Retained Earnings | $- | $-3.63B | $-3.60B | $-3.58B | $-3.47B | $-3.42B | $-3.42B | $-3.34B | $-3.27B | $-3.14B | $-2.99B | $-2.82B | $-2.64B | $-2.42B | $-2.25B | $-2.08B | $-1.97B | $-1.53B | $-1.31B | $-1.23B |
| Accumulated Other Comprehensive Income Loss | $-944.00K | $4.63M | $-943.00K | $-499.00K | $1.43M | $-1.53M | $-723.00K | $-1.72M | $-5.24M | $-11.07M | $-8.64M | $-6.65M | $-1.44M | $133.00K | $67.00K | $364.00K | $526.00K | $1.08M | $1.49M | $-1.72M |
| Other Total Stockholders Equity | $2.40B | $6.84B | $6.79B | $6.71B | $6.61B | $6.54B | $6.48B | $6.40B | $6.31B | $6.26B | $6.20B | $6.09B | $6.03B | $5.88B | $5.81B | $5.72B | $4.79B | $3.87B | $3.82B | $3.76B |
| Total Stockholders Equity | $2.40B | $3.21B | $3.19B | $3.13B | $3.15B | $3.12B | $3.06B | $3.06B | $3.04B | $3.11B | $3.21B | $3.26B | $3.39B | $3.46B | $3.56B | $3.65B | $2.82B | $2.34B | $2.51B | $2.54B |
| Total Equity | $2.40B | $3.21B | $3.19B | $3.13B | $3.15B | $3.12B | $3.06B | $3.06B | $3.04B | $3.11B | $3.21B | $3.26B | $3.39B | $3.46B | $3.56B | $3.65B | $2.82B | $2.34B | $2.51B | $2.54B |
| Total Liabilities and Stockholders Equity | $5.93B | $6.75B | $6.67B | $6.38B | $6.47B | $6.42B | $6.36B | $6.30B | $6.23B | $6.31B | $6.44B | $6.49B | $6.68B | $6.65B | $6.72B | $6.73B | $4.93B | $4.35B | $4.47B | $4.46B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.93B | $6.75B | $6.67B | $6.38B | $6.47B | $6.42B | $6.36B | $6.30B | $6.23B | $6.31B | $6.44B | $6.49B | $6.68B | $6.65B | $6.72B | $6.73B | $4.93B | $4.35B | $4.47B | $4.46B |
| Total Investments | $437.14M | $432.30M | $433.84M | $304.61M | $172.27M | $139.79M | $171.35M | $277.28M | $389.56M | $433.81M | $514.62M | $627.20M | $715.00M | $944.69M | $943.86M | $274.15M | $348.70M | $476.32M | $518.73M | $530.06M |
| Total Debt | $2.75B | $2.76B | $2.78B | $2.56B | $2.55B | $2.48B | $2.48B | $2.53B | $2.45B | $2.45B | $2.45B | $2.38B | $2.36B | $2.38B | $2.38B | $2.37B | $1.46B | $1.71B | $1.68B | $1.67B |
| Net Debt | $2.15B | $2.17B | $2.25B | $2.21B | $1.95B | $1.89B | $1.88B | $2.11B | $2.20B | $2.21B | $2.23B | $2.19B | $2.05B | $2.11B | $2.02B | $1.27B | $-27.11M | $907.00M | $980.03M | $964.81M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-1.03B | $-204.15M | $-623.51M | $-595.62M | $-848.53M |
| Depreciation and Amortization | $214.86M | $206.61M | $197.56M | $180.35M | $163.36M |
| Deferred Income Tax | $-10.12M | $-955.00K | $-11.90M | $-253.17M | $-9.86M |
| Stock Based Compensation | $214.88M | $231.31M | $206.82M | $339.23M | $152.91M |
| Change in Working Capital | $- | $-342.00K | $-26.38M | $111.11M | $-42.73M |
| Accounts Receivables | $-46.26M | $-43.42M | $61.09M | $25.15M | $-100.53M |
| Inventory | $-34.91M | $-7.69M | $-13.23M | $-9.22M | $-30.31M |
| Accounts Payables | $43.54M | $82.75M | $-52.18M | $153.12M | $46.38M |
| Other Working Capital | $- | $-31.99M | $-22.05M | $-57.94M | $41.73M |
| Other Non Cash Items | $819.77M | $-76.36M | $33.84M | $202.04M | $721.34M |
| Net Cash Provided by Operating Activities | $210.54M | $156.12M | $-223.56M | $-102.24M | $136.48M |
| Investments in Property Plant and Equipment | $-135.99M | $-124.19M | $-214.46M | $-135.77M | $-64.35M |
| Acquisitions Net | $-45.00M | $-68.98M | $-57.51M | $-517.77M | $-22.61M |
| Purchases of Investments | $-466.76M | $-156.42M | $-131.49M | $-1.16B | $-1.09B |
| Sales Maturities of Investments | $205.82M | $382.95M | $453.07M | $794.32M | $886.67M |
| Other Investing Activities | $-225.00K | $16.31M | $24.45M | $-58.82M | $-411.80M |
| Net Cash Used for Investing Activities | $-442.15M | $49.68M | $74.07M | $-1.08B | $-702.04M |
| Debt Repayment | $216.75M | $137.98M | $50.00M | $-23.75M | $974.24M |
| Common Stock Issued | $- | $31.54M | $6.52M | $37.51M | $861.70M |
| Common Stock Repurchased | $31.23M | $28.34M | $25.49M | $23.07M | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $15.12M | $21.79M | $26.48M | $32.22M | $43.68M |
| Net Cash Used Provided by Financing Activities | $231.87M | $159.77M | $76.48M | $8.47M | $1.88B |
| Effect of Forex Changes on Cash | $-3.29M | $1.32M | $30.00K | $23.00K | $- |
| Net Change in Cash | $-3.04M | $366.88M | $-72.98M | $-1.18B | $1.31B |
| Cash at End of Period | $606.64M | $609.67M | $242.79M | $315.77M | $1.49B |
| Cash at Beginning of Period | $609.67M | $242.79M | $315.77M | $1.49B | $177.53M |
| Operating Cash Flow | $210.54M | $156.12M | $-223.56M | $-102.24M | $136.48M |
| Capital Expenditure | $-135.99M | $-124.19M | $-214.46M | $-135.77M | $-64.35M |
| Free Cash Flow | $74.55M | $31.93M | $-438.02M | $-238.00M | $72.13M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $- | $-38.24M | $-15.81M | $-110.23M | $-49.77M | $794.00K | $-81.03M | $-74.15M | $-127.75M | $-148.76M | $-166.06M | $-180.94M | $-220.61M | $-166.94M | $-176.91M | $-31.16M | $-436.81M | $-219.88M | $-86.14M | $-105.70M |
| Depreciation and Amortization | $53.15M | $54.77M | $53.00M | $53.94M | $54.17M | $52.25M | $50.44M | $49.74M | $49.48M | $48.57M | $51.86M | $47.65M | $45.12M | $46.20M | $45.32M | $43.70M | $39.82M | $43.14M | $41.06M | $39.34M |
| Deferred Income Tax | $- | $-398.00K | $428.00K | $1.80M | $-676.00K | $-951.00K | $-589.00K | $1.26M | $-2.56M | $-4.41M | $-3.03M | $-1.91M | $-4.45M | $-4.21M | $-1.38M | $-243.13M | $-1.89M | $-4.75M | $-1.30M | $-1.92M |
| Stock Based Compensation | $49.20M | $48.73M | $56.55M | $60.40M | $58.58M | $61.90M | $61.70M | $49.14M | $45.92M | $49.50M | $58.93M | $52.44M | $55.88M | $63.60M | $56.28M | $77.29M | $41.83M | $41.48M | $40.04M | $29.56M |
| Change in Working Capital | $-21.47M | $44.43M | $29.24M | $-108.21M | $26.66M | $-24.57M | $54.42M | $-56.84M | $68.36M | $-19.68M | $953.00K | $-76.00M | $93.86M | $-15.96M | $70.88M | $-37.67M | $28.17M | $-10.83M | $-16.33M | $-43.73M |
| Accounts Receivables | $- | $-509.00K | $-23.36M | $-37.54M | $-3.11M | $-19.81M | $4.94M | $-25.43M | $33.12M | $-2.66M | $19.61M | $11.02M | $39.19M | $-23.03M | $31.95M | $-22.95M | $-26.88M | $-43.00M | $-24.32M | $-6.32M |
| Inventory | $- | $-9.61M | $1.16M | $-1.06M | $5.38M | $-543.00K | $-6.70M | $-5.83M | $-3.53M | $473.00K | $-2.21M | $-7.96M | $-8.13M | $-5.36M | $1.03M | $3.23M | $-11.84M | $1.79M | $-12.79M | $-7.47M |
| Accounts Payables | $- | $56.12M | $35.65M | $-53.52M | $31.67M | $2.33M | $53.57M | $-4.82M | $-52.18M | $-9.93M | $-13.29M | $-66.05M | $169.80M | $32.47M | $39.02M | $-15.86M | $55.16M | $38.84M | $-32.08M | $-18.30M |
| Other Working Capital | $-21.47M | $-1.57M | $15.80M | $-16.09M | $-7.29M | $-6.54M | $2.61M | $-20.77M | $90.94M | $-7.56M | $-3.15M | $-13.01M | $-107.00M | $-20.04M | $-1.13M | $-2.09M | $11.73M | $-8.46M | $52.86M | $-11.65M |
| Other Non Cash Items | $-33.81M | $29.43M | $132.75M | $13.15M | $-19.41M | $-65.03M | $77.16M | $-7.36M | $18.58M | $33.82M | $-3.57M | $-14.99M | $5.62M | $36.53M | $46.14M | $113.74M | $440.28M | $232.62M | $15.81M | $32.62M |
| Net Cash Provided by Operating Activities | $47.06M | $138.72M | $107.06M | $-82.31M | $69.55M | $24.36M | $100.42M | $-38.22M | $52.04M | $-40.93M | $-60.92M | $-173.75M | $-24.57M | $-40.77M | $40.34M | $-77.23M | $111.40M | $81.78M | $-6.87M | $-49.83M |
| Investments in Property Plant and Equipment | $-36.32M | $-26.16M | $-35.87M | $-37.65M | $-34.92M | $-25.19M | $-34.72M | $-29.36M | $-72.88M | $-44.64M | $-63.33M | $-33.62M | $-59.39M | $-38.87M | $-24.58M | $-12.92M | $-16.57M | $-14.33M | $-20.77M | $-12.69M |
| Acquisitions Net | $- | $-44.76M | $- | $-237.00K | $-21.98M | $-40.82M | $-5.73M | $-442.00K | $-31.37M | $-160.00K | $-24.81M | $-1.17M | $-88.67M | $-3.56M | $-72.30M | $-353.25M | $-5.34M | $-10.61M | $153.00K | $-6.81M |
| Purchases of Investments | $- | $-81.36M | $-147.62M | $-177.32M | $-64.76M | $-24.44M | $-42.07M | $-8.59M | $-29.05M | $-23.33M | $-8.84M | $-70.27M | $-142.49M | $-106.27M | $-752.79M | $-162.50M | $-199.94M | $-249.93M | $-214.92M | $-425.17M |
| Sales Maturities of Investments | $- | $70.58M | $36.36M | $43.98M | $54.90M | $57.23M | $149.49M | $121.33M | $75.63M | $108.13M | $118.68M | $150.63M | $369.49M | $99.45M | $89.08M | $236.29M | $326.77M | $291.42M | $229.34M | $39.14M |
| Other Investing Activities | $-5.56M | $-20.00K | $-111.26M | $-205.00K | $500.00K | $250.00K | $-500.00K | $112.30M | $-500.00K | $25.00M | $-42.00K | $-7.00K | $-500.00K | $-10.37M | $-33.18M | $-25.14M | $-411.56M | $272.00K | $-186.00K | $-330.00K |
| Net Cash Used for Investing Activities | $-41.87M | $-81.72M | $-147.13M | $-171.44M | $-66.77M | $-32.97M | $66.47M | $82.94M | $-58.16M | $65.00M | $21.66M | $45.56M | $78.44M | $-49.24M | $-793.77M | $-317.51M | $-306.64M | $16.83M | $-6.38M | $-405.85M |
| Debt Repayment | $- | $- | $216.75M | $- | $- | $- | $- | $137.98M | $- | $- | $50.00M | $- | $- | $- | $- | $- | $- | $- | $- | $975.49M |
| Common Stock Issued | $- | $-19.40M | $19.40M | $- | $-109.33M | $1.08M | $852.00K | $138.94M | $6.52M | $941.00K | $16.27M | $4.28M | $14.44M | $1.75M | $14.90M | $8.76M | $27.08M | $- | $- | $- |
| Common Stock Repurchased | $- | $20.77M | $-1.36M | $- | $28.34M | $- | $- | $- | $9.96M | $- | $15.53M | $- | $23.07M | $- | $- | $- | $18.36M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-25.41M | $- | $- | $- | $-986.55M | $- | $- | $- |
| Other Financing Activities | $10.50M | $-226.00K | $7.85M | $-3.00M | $10.04M | $92.00K | $16.04M | $-4.38M | $10.10M | $235.00K | $13.41M | $2.73M | $-24.29M | $81.00K | $13.34M | $7.25M | $879.86M | $4.16M | $16.12M | $3.99M |
| Net Cash Used Provided by Financing Activities | $10.50M | $-226.00K | $224.60M | $-3.00M | $10.04M | $92.00K | $16.04M | $133.60M | $10.10M | $235.00K | $63.41M | $2.73M | $-12.20M | $81.00K | $13.34M | $7.25M | $879.86M | $4.16M | $16.12M | $979.48M |
| Effect of Forex Changes on Cash | $-3.72M | $1.87M | $-306.00K | $-1.14M | $1.95M | $-1.24M | $59.00K | $550.00K | $3.21M | $-2.43M | $-510.00K | $-237.00K | $23.00K | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $11.97M | $64.49M | $182.69M | $-257.89M | $14.77M | $-9.75M | $183.00M | $178.87M | $7.19M | $21.89M | $23.64M | $-125.69M | $41.69M | $-89.94M | $-740.09M | $-387.49M | $684.62M | $102.76M | $2.87M | $523.81M |
| Cash at End of Period | $606.64M | $594.67M | $530.18M | $351.78M | $609.67M | $594.91M | $604.66M | $421.66M | $242.79M | $235.60M | $213.72M | $190.07M | $315.77M | $274.08M | $364.01M | $1.10B | $1.49B | $806.97M | $704.21M | $701.33M |
| Cash at Beginning of Period | $594.67M | $530.18M | $347.49M | $609.67M | $594.91M | $604.66M | $421.66M | $242.79M | $235.60M | $213.72M | $190.07M | $315.77M | $274.08M | $364.01M | $1.10B | $1.49B | $806.97M | $704.21M | $701.33M | $177.53M |
| Operating Cash Flow | $47.06M | $138.72M | $107.06M | $-82.31M | $69.55M | $24.36M | $100.42M | $-38.22M | $52.04M | $-40.93M | $-60.92M | $-173.75M | $-24.57M | $-40.77M | $40.34M | $-77.23M | $111.40M | $81.78M | $-6.87M | $-49.83M |
| Capital Expenditure | $-36.32M | $-26.16M | $-35.87M | $-37.65M | $-34.92M | $-25.19M | $-34.72M | $-29.36M | $-72.88M | $-44.64M | $-63.33M | $-33.62M | $-59.39M | $-38.87M | $-24.58M | $-12.92M | $-16.57M | $-14.33M | $-20.77M | $-12.69M |
| Free Cash Flow | $10.75M | $112.56M | $71.20M | $-119.96M | $34.63M | $-826.00K | $65.70M | $-67.58M | $-20.84M | $-85.56M | $-124.24M | $-207.38M | $-83.96M | $-79.64M | $15.75M | $-90.15M | $94.83M | $67.45M | $-27.64M | $-62.51M |
Exact Sciences Dividends
Explore Exact Sciences's dividend history, including dividend yield, payout ratio, and historical payments.
Exact Sciences News
Read the latest news about Exact Sciences, including recent articles, headlines, and updates.
Exact Sciences Schedules First Quarter 2025 Earnings Call
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursd.
New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency
BAAR, Switzerland--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score® test at the 19th St. Gallen International Breast Cancer Conference in Vienna, Austria. A UK study1 explored the benefits of shifting the testing point to the pre-surgery setting by utilizing Oncotype DX on breast cancer core biopsy samples instead of surgical speci.
2 Stocks Down 59% and 34% to Buy and Hold
Warren Buffett, arguably the greatest investor of all time, once said it is wise for investors to be fearful when others are greedy. One way to apply this advice from the Oracle of Omaha is to look at a soaring stock market and identify companies that aren't performing nearly as well -- or are just performing poorly -- but still have attractive prospects.
Exact Sciences to Participate in March Investor Conferences
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. TD Cowen Health Care Conference, Boston Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET Raymond James Institutional Investors Conference, Orlando Presentation on Tuesday, March 4, 2025 at 1:05 p.m. ET The webcasts can be acces.
Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point
Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss due to an $838M impairment charge from the Thrive acquisition. Despite the negative market reaction, Exact's core business shows momentum, with strong demand for Cologuard and a solid cash position of $1.04B. The company has ambitious 2025 revenue guidance and expects new product launches to drive growth, aiming for sustained profitability and long-term value.
Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Catherine Schulte - Baird Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Jack Meehan - Nephron Research Andrew Brackmann - William Blair Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Subu Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Dan Leonard - UBS Bill Bonello - Craig Hallum Sung Ji Nam - Scotiabank Eve Burstein - Bernstein Research Andrew Cooper - Raymond James Kyle Mikson - Canaccord Operator Good day, everyone, and welcome to the Exact Sciences Fourth Quarter 2024 Earnings Call. Today's call is being recorded.
Exact Sciences Announces Fourth Quarter 2024 Results
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $713 million for the fourth quarter of 2024 and $2.76 billion for the full year of 2024, both ended December 31, 2024. “The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the fourth quarter,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “This year is on track t.
U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact Sciences
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that the U.S. Patent Trial and Appeal Board instituted inter partes review of U.S. Patent No. 11,970,746 owned by Exact Sciences.
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2024 webcast & conference call details Date.
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 11 abstracts at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) meeting January 23-25, 2025, in San Francisco. “The data we are presenting at ASCO GI underscore Exact Sciences' leadership in advancing scientific innovation to drive meaningful progress in cancer detection and patient care,” said Jorge Garces, PhD, ch.
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared clinical validation data for its OncodetectTM MRD test at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI.) Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity dur.
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ended December 31, 2024. "The Exact Sciences team delivered strong results to finish 2024, setting us up for sustained growth and profitability in the years to come," said Kevin Conroy, chairman and CEO. "We look forward to expanding our impact as the platform supporting.
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 13, 2025 at 1:30 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.
AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates
ALEXANDRIA, Va., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA) is proud to announce a new project, made possible through a grant from Exact Sciences, that aims to improve colorectal cancer screening rates.Physician associates/physician assistants (PAs) are often one of the first healthcare providers a patient sees, and thus are uniquely positioned to discuss screenings early on with patients.AAPA Chief Medical Officer Jennifer M. Orozco-Kolb, DMSc, PA-C, DFAAPA, said PAs play an important role in educating and encouraging patients to complete colorectal cancer screenings.“The 5-year survival rate for a patient who is diagnosed with colorectal cancer in the early stages is upward of 91%,” Orozco-Kolb said. “When a patient is diagnosed at a later stage, that survival rate drops to almost 14%. Screening through either at home DNA stool testing or traditional colonoscopy procedures should be considered when having conversations with patients about what works best for them.”The project consists of three phases. The first phase, which is underway, will feature focus group meetings with four federally qualified health centers (FQHCs) in Wisconsin and Arizona that previously received Exact Sciences funding to complete projects that improved colorectal cancer screening rates. These FQHCs were selected because they often serve underserved or uninsured patients who are less likely to access and complete colorectal cancer screenings.These focus group meetings are expected to be completed by February 2025, when the second phase of the project will begin. This phase involves taking lessons learned and best practices gathered during the focus groups and creating an innovative toolkit that can be widely used by providers across the country to improve their own colorectal cancer screening rates.The third phase will consist of taking the newly developed toolkit and implementing changes at select clinics across the country to measure outcomes.In 2024, the American Cancer Society ranked colorectal cancer as the third deadliest form of cancer in men, and fourth deadliest cancer in women. It's estimated that more than 152,000 people nationwide will be diagnosed with colorectal cancer this year.### Media Contacts: AAPA: Josh Birch, 443.614.5896 About the American Academy of Physician Associates (AAPA) AAPA is the national membership organization for all physician associates/physician assistants (PAs). PAs are licensed clinicians who practice medicine in every specialty and setting. Trusted, rigorously educated and trained healthcare professionals, PAs are dedicated to expanding access to care and transforming health and wellness through patient-centered, team-based medical practice. Learn more about the profession at aapa.org and engage through Facebook, LinkedIn, Instagram, and Twitter.
Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 7:30 AM ET Company Participants Kevin Conroy - CEO Aaron Bloomer - CFO Conference Call Participants Vijay Kumar - Evercore Vijay Kumar Great. Thanks everyone for joining us this morning.
Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly Thanks, everybody, for joining us here at the conference. Happy to have Kevin Conroy and Aaron Bloomer from Exact Sciences with us here today.
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has teamed up with multi-platinum, Grammy award-winning artist Lil Jon on the “Get Low #2” campaign to increase screening for colon cancer, the nation's #2 cancer-related killer.2 The partnership also highlights the Cologuard® test as an effective, non-invasive tool to help improve screening rates for adults 45 and older who are eligible. The stool-based Cologuard test overcomes co.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for EXAS.